Accueil>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Ibafloxacine (R835)

Ibafloxacine (R835)

Catalog No.GC33988

L'ibafloxacine (R835) (R835) est un agent antibiotique fluoroquinolone développé exclusivement pour un usage vétérinaire.

Products are for research use only. Not for human use. We do not sell to patients.

Ibafloxacine (R835) Chemical Structure

Cas No.: 91618-36-9

Taille Prix Stock Qté
1mg
717,00 $US
En stock
5mg
1 434,00 $US
En stock
10mg
2 436,00 $US
En stock
20mg
4 302,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Ibafloxacine (R835) is a fluoroquinolone antibiotic agent that is developed exclusively for veterinary use.

The pharmacokinetic behavior of Ibafloxacin is studied after intravenous administration of a single dose of 15 mg/kg to 6 healthy lactating goats. Plasma concentrations of Ibafloxacin are determined by high-performance liquid chromatography with fluorescence detection. After IV injection Ibafloxacin shows very rapid initial distribution, with a mean half-life of 0.35 h, follows by slower elimination, with a mean half-life of 3.76 h. The elimination half-life of Ibafloxacin after oral administration has been reported to be 3.83 h in dogs and 3.00 h in cats[1].

[1]. Marín P, et al. Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats. Can J Vet Res. 2007 Jan;71(1):74-6.

Avis

Review for Ibafloxacine (R835)

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ibafloxacine (R835)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.